A study of PMN-310 for Alzheimer's disease

Next Previous
Trial Profile

A study of PMN-310 for Alzheimer's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs PMN 310 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Sep 2017 According to a ProMIS Neurosciences media release, the molecule PMN310 is on track for initiation of this trial in 2019.
    • 05 Apr 2017 New trial record
    • 30 Mar 2017 According to a ProMIS Neurosciences media release, the company expects to file an Investigational New Drug application and initiate the trial in late 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top